Elevated defibrillation threshold with venlafaxine therapy

Pharmacotherapy

Volumn 24, Issue 8, 2004, Pages 1095-1098

  Carnes, Cynthia A ^a,b   Pickworth, Kerry K ^c   Votolato, Nicholas A ^c   Raman, Subha V ^b,d  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^d Immunology and Medical Genetics   (United States)

Author keywords

Cardiac sodium channels; Implantable cardioverter defibrillator; QRS interval; Venlafaxine

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CALCIUM; CARVEDILOL; CLONAZEPAM; FUROSEMIDE; MAGNESIUM OXIDE; MILRINONE; MOXIFLOXACIN; MULTIVITAMIN; POTASSIUM CHLORIDE; SODIUM CHANNEL BLOCKING AGENT; SPIRONOLACTONE; VANCOMYCIN; VENLAFAXINE;

ADULT; ARTICLE; CARDIOMYOPATHY; CASE REPORT; COMORBIDITY; DEFIBRILLATION; DEFIBRILLATOR; DEPRESSION; FEMALE; HEART ARREST; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; PHYSICAL EXAMINATION; QRS COMPLEX; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DEFIBRILLATORS, IMPLANTABLE; DEPRESSIVE DISORDER, MAJOR; EQUIPMENT FAILURE; FEMALE; HEART ARREST; HUMANS;

EID: 3543053387     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.11.1095.36134     Document Type: Article

References (18)

1. Janse MJ. A brief history of sudden cardiac death and its therapy. Pharmacol Ther 2003;100:89-99.
2. Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). J Cardiovasc Electrophysiol 2002;13:1183-99.
3. Sears SF Jr, Todaro JF, Lewis TS, Sotile W, Conti JB. Examining the psychosocial impact of implantable cardioverter defibrillators: a literature review. Clin Cardiol 1999;22:481-9.
4. Hegel MT, Griegel LE, Black C, Goulden L, Ozahowski T. Anxiety and depression in patients receiving implanted cardioverter-defibrillators: a longitudinal investigation. Int J Psychiatry Med 1997;27:57-69.
5. Freedland KE, Rich MW, Skala JA, Carney RM, Davila-Roman VG, Jaffe AS. Prevalence of depression in hospitalized patients with congestive heart failure. Psychosom Med 2003;65:119-28.
6. Koenig HG. Depression in hospitalized older patients with congestive heart failure. Gen Hosp Psychiatry 1998;20:29-43.
7. Pasic J, Levy WC, Sullivan MD. Cytokines in depression and heart failure. Psychosom Med 2003;65:181-93.
8. Carnes CA, Mehdirad AA, Nelson SD. Drug and defibrillator interactions. Pharmacotherapy 1998;18:516-25.
9. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998;59:502-8.
10. Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM 2003;96:369-74.
11. Fukuda T, Nishida Y, Zhou Q, Yamamoto I, Kondo S, Azuma J. The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population. Eur J Clin Pharmacol 2000;56:175-80.
12. Kennedy SH, McCann SM, Masellis M, et al. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry 2002;63:181-6.
13. Gex-Fabry M, Balant-Gorgia AE, Balant LP, Rudaz S, Veuthey JL, Bertschy G. Time course of clinical response to venlafaxine: relevance of plasma level and chirality. Eur.J Clin Pharmacol 2004;59:883-91.
14. Stahlman R, Lode H. Fluoroquinolones in the elderly: safety considerations. Drugs Aging 2003;20:289-302.
15. Mehdirad AA, Carnes CA, Nelson SD. The influence of specific and nonspecific potassium current blockade on the defibrillation energy requirement of biphasic shock. Pacing Clin Electrophysiol 1999;22:147-51.
16. Melichercik J, Goepfrich M, Breidenbach T, Von Hodenberg E. Rise of defibrillation energy requirement under carvedilol therapy. Pacing Clin Electrophysiol 2001;24:1417-19.
17. Wang CM, Parker CH Jr, Maxwell RA. Electrophysiological effects of antidepressants on mammalian hearts and crayfish giant axon. J Cardiovasc Pharmacol 1981;3:101-12.
18. Alvarez W Jr, Pickworth KK. Safety of antidepressant drugs in the patient with cardiac disease: a review of the literature. Pharmacotherapy 2003;23:754-71.